A Threshold in Anti–EBNA-1 Antibody Titers Distinguishes Salivary EBV Shedders From Nonshedders - Summary - MDSpire

A Threshold in Anti–EBNA-1 Antibody Titers Distinguishes Salivary EBV Shedders From Nonshedders

  • By

  • João Vitor Mahler

  • Philippe A Bilodeau

  • Monique Anderson

  • Takahisa Mikami

  • Natasha Bobrowski-Khoury

  • Mulan Jiang

  • Huimin Zhu

  • James Nguyen

  • Marcelo Matiello

  • Michael Levy

  • Kjetil Bjornevik

  • Natalia Drosu

  • January 6, 2026

  • 0 min

Share

Objective:

To investigate whether individuals with exceptionally low anti–EBNA-1 antibody levels represent a distinct subgroup with reduced EBV shedding and restricted antibody diversity.

Key Findings:
  • Typical-range participants frequently shed EBV, while low outliers had no detectable shedding (P = .0002).
  • Nonshedders exhibited restricted antibody diversity limited to latent and immediate–early antigens.
  • All participants were confirmed EBV positive, indicating that low outliers suppress viral replication despite harboring latent virus.
Interpretation:

The study identifies a distinct nonshedder phenotype characterized by low anti–EBNA-1 levels, suggesting enhanced viral suppression and limited reactivation.

Limitations:
  • Small sample size of low outlier participants (n=3) may limit generalizability.
  • Study conducted in a single geographic location may not reflect broader populations.
Conclusion:

Individuals with exceptionally low anti–EBNA-1 antibody levels represent a unique subgroup with significant implications for understanding EBV-related disease susceptibility.

Original Source(s)

A Threshold in Anti–EBNA-1 Antibody Titers Distinguishes Salivary EBV Shedders From Nonshedders

  • by João Vitor Mahler, Philippe A Bilodeau, Monique Anderson, Takahisa Mikami, Natasha Bobrowski-Khoury, Mulan Jiang, Huimin Zhu, James Nguyen, Marcelo Matiello, Michael Levy, Kjetil Bjornevik, Natalia Drosu

  • January 6, 2026

Related Content

Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation